Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;25(2):139-148.
doi: 10.3747/co.25.3790. Epub 2018 Apr 30.

Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach

E Klimant  1 , H Wright  2 , D Rubin  2 , D Seely  3 , M Markman  4
Affiliations
Review

Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach

E Klimant et al. Curr Oncol. 2018 Apr.

Abstract

This article reviews intravenous vitamin C (IV C) in cancer care and offers a rational approach to enable medical oncologists and integrative practitioners to safely provide IV C combined with oral vitamin C to patients. The use of IV C is a safe supportive intervention to decrease inflammation in the patient and to improve symptoms related to antioxidant deficiency, disease processes, and side effects of standard cancer treatments. A proposed rationale, together with relevant clinical safety considerations for the application of IV C in oncologic supportive care, is provided.

Keywords: Vitamin C deficiency; ascorbate; intravenous vitamin C; quality of life; supportive care.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
At doses less than 25 g, intravenous vitamin C maximally adds to the antioxidant value of blood plasma. Reprinted, with permission, from Mikirova et al., 2007.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cameron E, Campbell A. The orthomolecular treatment of cancer. ii. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9:285–315. doi: 10.1016/0009-2797(74)90019-2. - DOI - PubMed
    1. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75:4538–42. doi: 10.1073/pnas.75.9.4538. - DOI - PMC - PubMed
    1. Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24:269–76. - PubMed
    1. Hoffer LJ, Levine M, Assouline S, et al. Phase i clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969–74. doi: 10.1093/annonc/mdn377. [Erratum in: Ann Oncol 2008;19:2095] - DOI - PubMed
    1. Monti DA, Mitchell E, Bazzan AJ, et al. Phase i evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7:e29794. doi: 10.1371/journal.pone.0029794. - DOI - PMC - PubMed

MeSH terms